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Abstract
Objectives The aim of this study was to determine whether
11C-hydroxyephedrine (11C-HED) can predict adverse
events including all-cause death in Japanese patients with
left ventricular (LV) dysfunction.
Background Although 11C-HED PET has been used to
assess cardiac sympathetic innervation in various disease
conditions, data on their prognostic value are limited.
Methods Sixty patients (mean LVEF, 42 ± 14 %) with
LV dysfunction (42 ischemic and 18 non-ischemic heart
disease) underwent 11C-HED PET. Myocardial retention
was calculated for 11C-HED PET as a measure of cardiac
sympathetic neuronal integrity. Statistical analysis was
performed using Cox proportional hazards regression and
log-rank test.
Results Thirteen deaths (7 cardiac and 6 non-cardiac
deaths) occurred during a mean follow-up period of
33 ± 23 months. The patients with death were associated
with significantly lower 11C-HED retention (7.1 ± 2.1 vs
9.0 ± 2.4, p = 0.015) than those without death. The haz-
ard ratio for global 11C-HED retention per unit (/min) was
0.762 (p = 0.039), which remained significant in multi-
variate analysis. When the patients were divided into the
high (C8.5) and low (\8.5) 11C-HED retention groups, the
low 11C-HED retention group was associated with signifi-
cantly poorer survival than the high 11C-HED retention
group (p = 0.004).
Conclusion The low global 11C-HED retention is a marker
of poor overall survival in patients with LV dysfunction in
this study.
Keywords Nervous system  Radioisotopes 
Sympathetic  Tomography
Introduction
Despite recent advances in therapeutic options, heart
failure (HF) continues to be one of the leading causes of
mortality and morbidity in many countries [1]. It is well
known that autonomic nerve function plays an important
role in the pathogenesis and progression of HF [2], which
is associated with excessive activation of sympathetic
nerve activity [3], and reduction in functional neuronal
density [4, 5]. Positron emission tomography (PET) using
radio-labeled norepinephrine analogs such as 11C-hy-
droxyephedrine (11C-HED) has successfully been used to
assess global and regional pre-synaptic sympathetic neu-
ronal integrity of the heart [4, 6, 7]. As compared with
more widely available 123I- metaiodobenzylguanidine
(123I-MIBG) imaging [8, 9], it provides better tomo-
graphic image quality due to higher counting sensitivity
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and spatial resolution and the possibility of absolute
quantification by routine use of attenuation/scatter cor-
rection [10]. However, there are only a few data available
focusing on the prognostic value of 11C-HED PET [11,
12]; there is none from Japan. Moreover, no 11C-HED
PET studies have reported all-cause mortality, which is
increasingly being utilized as an unbiased endpoint in
clinical trials [13].
The aim of this study was to determine whether 11C-
HED can predict adverse events including all-cause death
in Japanese patients with left ventricular (LV) dysfunction.
Materials and methods
Study population
This was a retrospective analysis of observational study to
characterize HF using imaging biomarkers [10]. We con-
secutively screened 81 patients who had been referred to
The Medical and Pharmacological Research Center Foun-
dation as potential candidates of the study using the fol-
lowing criteria: (1) angiographically proven coronary heart
disease (CHD) or non-ischemic symptomatic HF, because
both disease conditions are known to cause abnormalities
in cardiac sympathetic neuronal integrity, (2) regional or
global (left ventricular ejection fraction (LVEF) of\50 %)
left ventricular (LV) dysfunction documented by echocar-
diography, (3) 11C-acetate/11C-HED PET having been
performed under stable general condition within 1 month
after the entry, and (4) could be followed-up for[6 months
in case of no events. The first criterion was met in all 81
patients; the second criterion in 74 patients; the third and
fourth criteria in 60 patients. Patients were excluded if they
(1) had unstabilized HF, (2) had acute coronary events
(\10 days) such as myocardial infarction or unstable ang-
ina prior to the imaging study, or (3) were premenopausal
women. There are none who met the exclusion criteria.
Thus, 60 patients were finally included in the study. All
cardiac medications such as beta-blockers were continued
during the study period for safety reasons. After giving a
written informed consent in accordance with institutional
ethical committee, all patients underwent 11C-HED/11C-
acetate PET imaging.
Positron emission tomography
The PET imaging was performed in a manner as described
previously [5] using a full-ring PET scanner (Advance, GE
Healthcare, Milwaukee, WI, USA). Briefly, transmission
scan for 15 min was performed using 68Ge/68Ga pin sour-
ces for attenuation correction. Then, 370 MBq of 11C-ac-
etate was intravenously injected, and a dynamic imaging
sequence (21 frames, 10 9 10, 1 9 60, 5 9 100, 3 9 80,
2 9 300 s) was acquired for 30 min. In this study, 11C-
acetate PET data were used to obtain relative perfusion
images, which was necessary to measure perfusion defect
size and mismatch size as mentioned later. Approximately
120 min after injection of 11C-acetate allowing for physical
decay of 11C, the subjects were re-positioned in the scanner
and a second transmission scan was acquired for 15 min.
This was followed by intravenous injection of
370–600 MBq of 11C-HED, and a subsequent dynamic
imaging for 40 min (14 frames, 6 9 30, 2 9 60, 2 9 150,
2 9 300, 2 9 600 s). The total radiation exposure for this
imaging procedure was estimated to be \3.4 mSv [14,
15]. Images obtained from a representative case were
shown in Fig. 1.
Fig. 1 A representative
example of 11C-acetate
perfusion defect size (left), 11C-
HED defect size (right), and
calculation of mismatch size
measurements using polar map
analysis. In this example,
perfusion defect size, 11C-HED
defect size, and mismatch size
were 32 %LV, 68 %LV, and
36 %LV, respectively
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Echocardiography
Echocardiography was performed in all patients on the
same day of PET imaging (between 11C-acetate and 11C-
HED scan) using Vivid 7 (GE Healthcare, Milwaukee, WI,
USA) with a 4 MHz transducer. LVEF was measured using
Simpson biplane method.
Processing of PET data
Attenuation-corrected transaxial images were reconstructed
using ordered subset expectation maximization algorithm.
The image data matrix was 128’’ 128 with pixel size of
2.73 mm and a slice thickness of 4.25 mm. A volumetric
sampling procedure was used to create polar maps of rel-
ative myocardial perfusion distribution throughout the
entire LV myocardium as described elsewhere. In brief,
summed data sets of frames 11–13 of the imaging sequence
for 11C-acetate were used to create polar maps of
myocardial activity distribution at 2–4 min after injection,
which served as a relative perfusion image.
To obtain global 11C-HED retention fraction, the 11C-
HED uptake averaged for the entire left ventricular myo-
cardium at 30–40 min image was divided by the integral of
blood activity curve, which served as a quantitative index
of cardiac sympathetic innervation. Then, the polar maps
were normalized to the mean of six connected sectors
showing the highest overall uptake in the left ventricular
myocardium. Defect size on the 11C-acetate flow image or
11C-HED image was quantified using a cutoff threshold of
60 % of the reference sectors and was expressed as a
percentage of the left ventricular myocardium (%LV).
Mismatch size was defined as 11C-HED defect size minus
11C-acetate perfusion defect size. Thus, global 11C-HED
retention, perfusion defect size, 11C-HED defect size, and
mismatch size were measured from PET imaging.
Follow-up
Clinical outcomes were confirmed by patient medical
records or telephone interview. The primary endpoint was
set to all-cause death; the secondary, cardiac death; and the
tertiary, the composite endpoint including HF progression
requiring hospitalization, life-threatening arrhythmias such
as ventricular tachycardia, and acute coronary syndrome,
or death of any cause. In case of multiple events, only the
first event was used for analysis.
Statistical analysis
Data were expressed as mean ± SD unless specified. Sta-
tistical analysis was performed using JMP10 (SAS Institute
Inc. Cary, NC, USA), or GraphPad Prism6 (GraphPad
Software, Inc. San Diego, CA, USA), where appropriate.
Wilcoxon rank sum test was used for comparison of vari-
ables between the two groups. Proportional difference
between the groups was assessed using Chi-square test.
Univariate and multivariate analyses using a Cox propor-
tional hazards model were performed. The multivariate
model for time to all-cause mortality, cardiac death, or
composite endpoint was evaluated using a stepwise for-
ward elimination procedure using variables including sex,
age, LVEF, BNP, global 11C-HED retention, 11C-HED
defect size, and mismatch size. In this study, we included
only quantitative or objective and discrete variables; those
such as NYHA class or presence of hypertension were not
included because they were subjective or not necessarily
discrete. In addition, the Kaplan–Meier method with log-
rank test was applied to obtain survival curves. Optimal
cut-off points for continuous variables were determined
retrospectively using receiver operating characteristic




The clinical characteristics and cause of death are sum-
marized in Table 1 and Supplemantary Table 1, respec-
tively. Of the 42 patients with ischemic etiology, prior
myocardial infarction was present in 32 patients. Of a total
of 60 patients enrolled, 13 died (7 cardiac and 6 non-car-
diac deaths) during the mean follow-up period of
33 ± 23 months (range 1–82, median: 24 months). Of the
Table 1 Clinical characteristics
Age (years) 70 ± 10, 71 (47–89)
Male/female (n) 43/17
Etiology
Ischemic (n, %) 42 (70 %)
Prior myocardial infarction (n, %) 32 (53 %)
DM (n, %) 25 (42 %)
HT (n, %) 41 (68 %)
NYHA class 1/2/3/4 15/33/11/1
Medication (n, %)
ACE-I or ARB 34 (57 %)
Aldosterone blocker 16 (27 %)
b-blocker 28 (47 %)
Diuretic 31 (52 %)
Nitrate 39 (65 %)
Ca-antagonist 37 (62 %)
Values are mean ± SD, median (range) or n (%)
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7 patients with cardiac death, 2 died of sudden cardiac
death and the remaining 5 of progression of HF. Cardiac
events occurred in 17 patients, including 13 HF progres-
sion, 2 acute coronary syndromes, and 2 life-threatening
arrhythmias.
All-cause mortality
Imaging parameters, patients characteristics, and serum
BNP levels in patients with and without all-cause death are
summarized in Table 2. The patients with death were
associated with a lower LVEF, lower global 11C-HED
retention, higher age, and higher serum BNP level than
those without death. However, there were no significant
differences in sex and perfusion defect size, although there
was a trend towards larger 11C-HED defect size or mis-
match size in patients with death than those without death.
The results of univariate and multivariate Cox hazards
analysis are summarized in Table 3. The univariate anal-
ysis identified age, BNP, and 11C-HED retention as a
predictor of all-cause death. In the multivariate analysis,
age and global 11C-HED retention remained significant.
When the patients were divided into the high (C8.5) and
low (\8.5) global 11C-HED retention groups based on
ROC analysis (Supplementary Fig. 1), the low 11C-HED
retention group was associated with significantly poorer
survival than the high 11C-HED retention group
(p = 0.004) (Fig. 2).
Other endpoints
Imaging parameters, patients characteristics, and serum
BNP levels in patients with and without cardiac death are
summarized in Supplementary Table 2. The patients with
death were associated with a higher serum BNP level than
those without death. Additionally, there was a trend toward
a lower LVEF and larger 11C-HED defect size in patients
with death than those without death. However, global 11C-
HED retention did not differ between the 2 groups. Using
univariate Cox hazards analysis, LVEF and serum BNP
level were significant predictors of cardiac death, of which
only serum BNP remained significant in multivariate
analysis (Supplemantary Table 3). The Kaplan–Meier
analysis showed no significant difference in survival curve
between the high (C8.4) and low (\8.4) global 11C-HED
retention groups (Fig. 2). When the composite endpoint
Table 2 Patients with or
without death
Survived (n = 47) Dead (n = 13) P value
Age (years) 69 ± 9 75 ± 12 0.038*
Female (n, %) 11 (23 %) 6 (46 %) 0.119
BNP (pg/ml) 176 ± 166 724 ± 1146 0.002*
LVEF (%) 44 ± 13 35 ± 15 0.038*
Perfusion defect size (%LV) 16 ± 17 19 ± 21 0.648
HED retention (/min) 9.0 ± 2.4 7.1 ± 2.1 0.015*
HED defect size (%LV) 30 ± 22 41 ± 26 0.129
Mismatch size (%LV) 14 ± 13 23 ± 20 0.063
Values are mean ± SD or n (%)
BNP B-type natriuretic peptide, LVEF left ventricular ejection fraction, metabolic index, HED 11C-
hydroxyephedrine
* Statistically significant variate (P\ 0.05)
Table 3 Results of univariate and multivariate Cox proportional hazards analysis for all-cause mortality
Variable Chi-square HR (CI) P value Chi-square HR (CI) p value
Age (per year) 10.86 1.126 (1.047–1.226) 0.001* 12.06 1.135 (1.053–1.243) 0.001*
Female 1.696 2.141 (0.666–6.607) 0.193
BNP (per 1 pg/mL) 8.620 1.001 (1.000–1.001) 0.003*
LVEF (per 1 %) 3.098 0.961 (0.916–1.004) 0.078
Perfusion defect size (per 1 % of LV) 0.018 0.998 (0.964–1.028) 0.895
HED retetion (per 1/min) 4.274 0.762 (0.580–0.986) 0.039* 5.476 0.759 (0.589–0.957) 0.019*
HED defect size (per 1 % of LV) 1.230 1.013 (0.990–1.038) 0.267
Mismatch size (per 1 % of LV) 3.351 1.030 (0.998–1.059) 0.067
* Statistically significant variate (P\ 0.05)
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was applied, the patients with event were associated with a
lower LVEF, lower global 11C-HED retention, and higher
serum BNP level than those without event (Supplementary
Table 4). Additionally, there was a trend toward larger 11C-
HED defect size or mismatch size in patients with event
than those without event. Using univariate Cox hazards
analysis, LVEF, global 11C-HED retention, mismatch size,
and serum BNP level were significant predictors of event,
of which only serum BNP remained significant in multi-
variate analysis (Supplementary Table 5). The Kaplan–
Meier analysis showed that the low (\8.9) 11C-HED
retention group was associated with significantly poorer
prognosis than the high (C8.9) 11C-HED retention group
(p = 0.012) (Fig. 2).
Discussion
The major findings of this study were that (1), of the
imaging parameters tested, global 11C-HED retention was a
significant predictor of all-cause death, whereas global 11C-
HED retention and mismatch size were predictors of the
composite endpoint; (2) in multivariate analysis, age and
global 11C-HED retention were independent predictors of
all-cause death, whereas only serum BNP remained a sig-
nificant predictor of cardiac death or composite endpoint.
Sympathetic neuronal imaging and its prognostic
value
There is a general consensus that cardiac sympathetic
neuronal function plays an important role for the patho-
genesis of HF [2]. It is also known that an elevated cir-
culating norepinephrine is a marker of poor outcome [17].
Using imaging techniques with radio-labeled nore-
pinephrine analogs such as 123I-MIBG, there are a number
of studies showing the prognostic value of cardiac sym-
pathetic neuronal imaging, where the patients with low
myocardial 123I-MIBG uptake as measured by semi-quan-
titative heart-to-mediastinum (H/M) uptake ratio are asso-
ciated with poor prognosis [8, 9, 16, 18–20]. As compared
to the aforementioned 123I-MIBG imaging, 11C-HED PET
is considered to be a more sophisticated technique with
higher image quality and opportunity of quantification of
absolute tracer uptake. Additionally, an advantage of 11C-
HED PET over 123I-MIBG imaging is that it provides
Fig. 2 Kaplan–Meier survival curves for all-cause mortality (upper left), cardiac death (upper right), and composite endpoint (lower left) of 2
groups classified by the cut-off value of global 11C-HED retention
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higher tomographic image quality and, therefore, is more
suitable for regional assessment, as demonstrated in our
previous study [10]. However, there are only two studies
that have systemically investigated the prognostic value of
11C-HED PET due to its limited availability. A retrospec-
tive study by Pietila et al. [11] of 46 patients with chronic
heart failure (CHF) indicated that CHF patients had sig-
nificantly lower global 11C-HED retention than healthy
subjects, and that patients with poor prognosis (death or
transplantation) had even lower retention. More recently,
Fallavollita et al. [12] have demonstrated that regional
myocardial sympathetic denervation assessed by 11C-HED
PET was predictive for the risk of sudden cardiac arrest in
204 ischemic HF patients who had undergone
implantable cardioverter defibrillator therapy. Our results
demonstrated that age and low global 11C-HED retention
were independent predictors of all-cause mortality, which
remained true when multivariate analysis was performed,
indicating that cardiac sympathetic dysinnervation as
measured by 11C-HED PET is related to poor survival in
patients with LV dysfunction independent of age. Regional
parameters such as 11C-HED defect size were not signifi-
cant predictors of all-cause mortality in this study, although
there was a trend toward larger perfusion/11C-HED mis-
match size in patients with death as compared to those
without death. This indicates that global rather than
regional sympathetic dysinnervation is a better marker of
overall mortality. An issue that needs to be addressed is
that all-cause mortality includes patients died of non-car-
diac disease, including those of malignancy, traffic acci-
dent, and unknown cause. Although the exact mechanisms
are not clear, it could be possible that the presence of
severe HF as reflected by low global 11C-HED retention
may have unfavorably affected overall survival even in
such patients.
Although all-cause mortality is considered to be an
objective and unbiased clinical endpoint, the selection of
endpoint is still a matter of debate [13]. Therefore, we
additionally assessed other endpoints such as cardiac death
and composite endpoint. Cardiac death is a cause-specific
and commonly used endpoint in clinical studies in patients
with heart disease [8, 9, 16, 18–20]. The results showed
that, although the patients with cardiac death tended to be
associated with a larger 11C-HED defect than those without
death, the PET derived parameters failed to show predic-
tive power for cardiac death. The small sample size as well
as potential misclassification of patients who actually died
of cardiac cause as non-cardiac may explain the results.
However, serum BNP level, a conventional parameter for
HF severity, was still a significant predictor of cardiac
death despite the small sample size, indicating that 11C-
HED parameters have less significant predictive power
than serum BNP in this setting. Thus, the prognostic value
of 11C-HED PET may differ depending on what endpoint is
chosen.
For the composite endpoint including any cardiac event
and any death, the patients with events were associated
with a lower global 11C-HED retention and higher serum
BNP level than those without event. However, in multi-
variate analysis, only serum BNP survived as a significant
predictor of the endpoint. Whether 11C-HED PET param-
eters would provide incremental prognostic value to serum
BNP needs to be addressed in larger trials in future.
A potential advantage of employing 11C-HED PET
instead of serum BNP would be that regional abnormalities
can be assessed using PET technique. As aforementioned, a
study by Fallavollita et al. [12] has demonstrated that
regional but not global denervation is a predictor of sudden
cardiac death. In our study, however, the prognostic value
of regional parameters such as HED defect size was not
clear mainly because of the limited sample size. Thus, our
data have demonstrated that measuring serum BNP is still
convenient and useful tool for prediction of cardiac event
in any underlying causes.
Limitations
There are limitations of the study that need to be men-
tioned. First, the retrospective nature of the study prevented
the enrollment of a homogeneous population. Additionally,
strict medication control was difficult, where the preva-
lence of patients with beta-blocker therapy (47 %) was
somewhat lower than that (66–96 %) reported in prior
imaging studies in HF particularly from western countries
[12, 20, 21]. However, this prevalence is not much dif-
ferent from that (54 %) reported in the largest meta-anal-
ysis study in Japan [16]. Second, due to the small number
of patients, we could not test some cause-specific endpoints
such as lethal arrhythmias. Because regional abnormalities
in sympathetic innervation is reportedly linked to ventric-
ular arrhythmias [12, 22, 23], this needs to be addressed in
further studies. Finally, our patient population consisted of
those with ischemic and non-ischemic etiology. In
ischemic HF, the presence or absence of prior myocardial
infarction may have an impact on prognosis. However,
such a specific analysis would require a larger number of
patients to draw definitive conclusions. A further study
with a large number of ischemic patients is required to
address this issue.
Conclusions
Our results indicate that age and low global 11C-HED
retention measured by PET are independent markers of
poor overall survival in Japanese patients with LV
466 Ann Nucl Med (2016) 30:461–467
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dysfunction in this study. Furthermore, the prognostic
value of 11C-HED PET may differ depending on what
endpoint is chosen.
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